Drugs / Tocotrienol
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 25 trials | ||||||
| Phase 2 | NCT04491383 | Apr 2021 → Jul 2026 overdue | Parkinson disease, neurodegenerative disease | National Neuroscience Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04245865 | Jun 2020 → Mar 2025 overdue | colorectal cancer | Vejle Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02909751 | Sep 2016 → Jan 2019 | breast cancer | Vejle Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04496492 | Feb 2016 | female breast carcinoma | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Completed | No outcome recorded |
| Phase 2 | NCT02399592 | Mar 2015 → Jul 2019 | ovarian cancer | Vejle Hospital | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02644252 | Jan 2016 → May 2019 | lung cancer | Vejle Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Comparator or background therapy3 trials | ||||||
| Phase 1/2 | NCT03708354 Comparator | Apr 2019 → Dec 2022 | — | Texas Tech University Health Sciences Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02581085 Comparator | Nov 2019 → Dec 2025 | NAFLD1, chronic liver failure, metabolic dysfunction-associated steatohepatitis | Chandan Sen | Completed | No outcome recorded |
| — | NCT00893724 Comparator | Jun 2009 → Aug 2011 | diabetic macular edema, wet macular degeneration | Mid-Atlantic Retina Consultations, Inc. | Unknown | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tocotrienol | “The purpose of this study is to to investigate the effect of tocotrienol as a nutritional supplement in combination with bevacizumab in patients with advanced ovarian cancer.” NCT02399592 ↗8“Dietary supplement: Tocotrienol (HOV-12020) Palm oil-derived vitamin E, tocotrienol” NCT04491383 ↗ “Dietary Supplement: Tocotrienol 300 mg x 3 daily” NCT02909751 ↗ “Tocotrienol 300 mg x 3 daily until progression.” NCT02644252 ↗ “Dietary Supplement: Tocotrienol” NCT04245865 ↗ |
| Known as | Tocotrienol, alpha | ChEMBL registry synonym — accepted as the source's own label CHEMBL120643 ↗ |
| Known as | tocotrienols | “A study using Parkinson's disease animal model, transgenic fruit flies, demonstrated the potential of using tocotrienols (HOV-12020) as a therapeutic agent for delaying...” NCT04491383 ↗ |
| Action | Inhibit | “posttranscriptional suppression of HMG-CoA reductase” PMID 1433170 ↗ Oct 1992 |
| Modality | Small molecule | “Tocotrienols are farnesylated benzopyran natural products” PMID 1433170 ↗ Oct 1992 |
| Route | Oral | “oral Tocotrienol (TCT) attenuates the rise in MELD score over time in patients with end stage liver disease / cirrhosis.” NCT02581085 ↗ |
| Target | HMGCR | “γδT3 suppressed the upstream regulators of lipid homeostasis genes (DGAT2, APOB100, SREBP1/2 and HMGCR)” PMID 20702976 ↗ Aug 2010 |